INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.63 USD | -0.56% |
|
-2.99% | -17.77% |
Financials (USD)
| Sales 2024 * | 4.13B | Sales 2025 * | 4.6B | Capitalization | 11.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 798M | Net income 2025 * | 1B | EV / Sales 2024 * | 1.75 x |
| Net cash position 2024 * | 4.37B | Net cash position 2025 * | 5.68B | EV / Sales 2025 * | 1.29 x |
| P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
11.8
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | -0.56% | ||
| 1 week | -2.07% | ||
| Current month | -9.37% | ||
| 1 month | -10.18% | ||
| 3 months | -15.14% | ||
| 6 months | -6.04% | ||
| Current year | -17.77% |
1 week
51.39
53.15
1 month
51.3957.59
Current year
51.3967.37
1 year
50.2775.74
3 years
50.2788.26
5 years
50.27110.37
10 years
43.44153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Pablo Cagnoni
PSD | President | 60 | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 215 M€ | +11.92% | - | |
| 2.94% | 1 M€ | 0.00% | - | |
| 2.88% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 51.65 | -0.52% | 2,493,676 |
| 24-04-22 | 51.92 | -0.82% | 1,751,676 |
| 24-04-19 | 52.35 | -0.89% | 2,181,297 |
| 24-04-18 | 52.82 | +0.19% | 1,830,343 |
| 24-04-17 | 52.72 | -0.94% | 2,525,527 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
51.92
USD
Average target price
75.58
USD
Spread / Average Target
+45.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.77% | 11.66B | |
| -2.43% | 85.68B | |
| +4.08% | 41.4B | |
| -25.35% | 28.22B | |
| +54.31% | 24.64B | |
| -4.52% | 16.98B | |
| -42.09% | 13.29B | |
| -12.10% | 11.65B | |
| +0.75% | 8.18B | |
| +3.32% | 7.78B |
- Stock Market
- Equities
- INCY Stock
